About
Here you'll find all the latest updates to the CMF site, as well as breaking news from the world of cardiometabolic diseases!
Latest Updates
All ▼
![EASD 2023](https://cardiometabolicforum.com/storage/3cb87FHMhllccP0lvS4spS37UO5P24mIuB0bT2g8.png)
59th Annual EASD 2023 - European Association for the study of Diabetes 2nd-6th Oct
![](https://cardiometabolicforum.com/storage/KJqzguOXVOZajPPWBFhDR5zbZ1YpcTq4GO8WNudk.png)
UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease
![FDA](https://cardiometabolicforum.com/storage/HsIp2gPtl5MZXj4PDXhAO5rdlwkaEgM7PIylnawP.jpg)
Brenzavvy (bexagliflozin) approved by the FDA in adults with type 2 diabetes mellitus as an adjunct to diet and exercise
![Publication thumbnail: Zibotentan in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease (ZENITH-CKD): a Multicentre, Randomised, Active-controlled, Phase 2b, Clinical Trial](https://cardiometabolicforum.com/storage/KjBDFroXyBl2h9ockfEAANfONApIGtewhSD9ZBmK.jpg)
Zibotentan in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease (ZENITH-CKD): a Multicentre, Randomised, Active-controlled, Phase 2b, Clinical Trial
![Publication thumbnail: Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial](https://cardiometabolicforum.com/storage/OWygpkFQkexAuAZnhamBrKCucFMuYtuHv21vlxOR.jpg)
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial
![Publication thumbnail: Glomerular and Tubular Effects of Dapagliflozin, Eplerenone and their Combination in Patients with Chronic Kidney Disease: A Post-hoc Analysis of the ROTATE-3 Study](https://cardiometabolicforum.com/storage/gbW6b9YsY5EFjSJaeUHztF8avILgzymGSN3VoJu2.jpg)
Glomerular and Tubular Effects of Dapagliflozin, Eplerenone and their Combination in Patients with Chronic Kidney Disease: A Post-hoc Analysis of the ROTATE-3 Study
![Publication thumbnail: Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial](https://cardiometabolicforum.com/storage/PnPSLAN02uAF5GtQQKkqOLT1VqQl62NaCgJPF2Im.jpg)
Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial
![Publication thumbnail: Tirzepatide after Intensive Lifestyle Intervention in Adults with Overweight or Obesity: the SURMOUNT-3 Phase 3 Trial](https://cardiometabolicforum.com/storage/AUK4i9cyYQBBdVAc5B8cElpvVNOcfvMDpZpyXbvS.jpg)
Tirzepatide after Intensive Lifestyle Intervention in Adults with Overweight or Obesity: the SURMOUNT-3 Phase 3 Trial
![Publication thumbnail: Efficacy of Finerenone in Patients with Type 2 Diabetes, Chronic Kidney Disease and Altered Markers of Liver Steatosis and Fibrosis: A FIDELITY Subgroup Analysis](https://cardiometabolicforum.com/storage/jjo2lGpT9BAuBivGVLfwSYXZqFevGOXjGVamK5uY.jpg)
Efficacy of Finerenone in Patients with Type 2 Diabetes, Chronic Kidney Disease and Altered Markers of Liver Steatosis and Fibrosis: A FIDELITY Subgroup Analysis
![Publication thumbnail: Relationship Between Body Weight Change and Glycaemic Control with Tirzepatide Treatment in People with Type 2 Diabetes: A Post Hoc Assessment of the SURPASS Clinical Trial Programme](https://cardiometabolicforum.com/storage/x3rlNjZLRR3Da9EKi4kIHUec1MjTYUMBALeDYfby.jpg)
Relationship Between Body Weight Change and Glycaemic Control with Tirzepatide Treatment in People with Type 2 Diabetes: A Post Hoc Assessment of the SURPASS Clinical Trial Programme
![Publication thumbnail: Albuminuria-Lowering Effect of Adding Semaglutide on Top of Empagliflozin in Individuals with Type 2 Diabetes: A Randomized and Placebo-Controlled Study](https://cardiometabolicforum.com/storage/AYdYE5IDjTz4ugmoL7a7G42nFbHdSP1Ant2LLTxo.jpg)
Albuminuria-Lowering Effect of Adding Semaglutide on Top of Empagliflozin in Individuals with Type 2 Diabetes: A Randomized and Placebo-Controlled Study
![Publication thumbnail: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity](https://cardiometabolicforum.com/storage/eeeCrUvF3ZGHnNpe2gBiuasSDTSgqU8E1mJL5EDL.jpg)
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
![Publication thumbnail: Mineralocorticoid Receptor Antagonist Use and the Effects of Empagliflozin on Clinical Outcomes in Patients Admitted for Acute Heart Failure: Findings from EMPULSE](https://cardiometabolicforum.com/storage/NXpMV3DuDwqcw4OfloJySlfSQGrCCRhkD84LpZ7P.jpg)
Mineralocorticoid Receptor Antagonist Use and the Effects of Empagliflozin on Clinical Outcomes in Patients Admitted for Acute Heart Failure: Findings from EMPULSE
![Publication thumbnail: Short-Term Costs in Patients with Chronic Kidney Disease Treated with Dapagliflozin: a Retrospective Cohort Study](https://cardiometabolicforum.com/storage/jhr6PdzKU5V5oWdH6V0al1NxaGWCKTtoDa6cYkUg.jpg)
Short-Term Costs in Patients with Chronic Kidney Disease Treated with Dapagliflozin: a Retrospective Cohort Study
![Publication thumbnail: The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials](https://cardiometabolicforum.com/storage/IpbzhZyT3Npa2Mj8AAlIc26sOPzFFdLUlcOsH9Dk.jpg)
The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
![Publication thumbnail: The Impact of Obesity on Cardiovascular and Kidney Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes Treated with Finerenone: Post hoc analysis of the FIDELITY Study](https://cardiometabolicforum.com/storage/Lrbon4h2MPyEya8iOfmUQFq0IGwth8Nu1PDIqvtN.jpg)
The Impact of Obesity on Cardiovascular and Kidney Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes Treated with Finerenone: Post hoc analysis of the FIDELITY Study
![Publication thumbnail: Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Elderly Patients with Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials](https://cardiometabolicforum.com/storage/UgymIKw2oJIVtNXVGrSEkzN7b4xAPAJqtcEfQWkh.jpg)
Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Elderly Patients with Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials
![Publication thumbnail: Mineralocorticoid Receptor Antagonist Use in Chronic Kidney Disease with Type 2 Diabetes: A Clinical Practice Document by the European Renal Best Practice (ERBP) Board of the European Renal Association (ERA)](https://cardiometabolicforum.com/storage/x9iY1MDPkHYXgcb1CR7KQlHyEQV3GJxYDPk5SSO8.jpg)
Mineralocorticoid Receptor Antagonist Use in Chronic Kidney Disease with Type 2 Diabetes: A Clinical Practice Document by the European Renal Best Practice (ERBP) Board of the European Renal Association (ERA)
![Publication thumbnail: Oral Semaglutide 50 mg Taken Once per Day in Adults with Overweight or Obesity (OASIS 1): a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial](https://cardiometabolicforum.com/storage/XKoM3nkS1RXH8rvDUcl5sYRH21vvBRyKSqejBqDQ.jpg)
Oral Semaglutide 50 mg Taken Once per Day in Adults with Overweight or Obesity (OASIS 1): a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
![Publication thumbnail: Efficacy and Safety of Oral Orforglipron in Patients with Type 2 Diabetes: A Multicentre, Randomised, Dose-Response, Phase 2 Study](https://cardiometabolicforum.com/storage/HMHlUydXrFAmIDAnKd8SqR1Cx3phwKjcayio4C2F.jpg)
Efficacy and Safety of Oral Orforglipron in Patients with Type 2 Diabetes: A Multicentre, Randomised, Dose-Response, Phase 2 Study
![Publication thumbnail: Efficacy and Safety of Co-Administered Once-weekly Cagrilintide 2.4 mg with Once-Weekly Semaglutide 2.4 mg in Type 2 Diabetes: a Multicentre, Randomised, Double-Blind, Active-Controlled, Phase 2 Trial](https://cardiometabolicforum.com/storage/b8ZEbbhgRhFLG2oEi3wh5C6t6xvBfxcWdwHAeVlf.jpg)
Efficacy and Safety of Co-Administered Once-weekly Cagrilintide 2.4 mg with Once-Weekly Semaglutide 2.4 mg in Type 2 Diabetes: a Multicentre, Randomised, Double-Blind, Active-Controlled, Phase 2 Trial
![Publication thumbnail: Effect of Semaglutide versus Other Glucagon-Like Peptide-1 Receptor Agonists on Cardio-Metabolic Risk Factors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Head-to-Head, Phase 3, Randomized Controlled Trials](https://cardiometabolicforum.com/storage/x3b8VsGicsLq9Mg1F4WutIUggJwlOUeiiJ8fvPAX.jpg)
Effect of Semaglutide versus Other Glucagon-Like Peptide-1 Receptor Agonists on Cardio-Metabolic Risk Factors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Head-to-Head, Phase 3, Randomized Controlled Trials
![Publication thumbnail: Efficacy and Safety of Tirzepatide for Treatment of Overweight or Obesity. A Systematic Review and Meta-analysis](https://cardiometabolicforum.com/storage/Q0NMPUbB3fxIZPe438eOVRIepw8euzB6KIff66HP.jpg)
Efficacy and Safety of Tirzepatide for Treatment of Overweight or Obesity. A Systematic Review and Meta-analysis
![Publication thumbnail: The Improved Health Utility of Once-Weekly Subcutaneous Semaglutide 2.4 mg Compared With Placebo in the STEP 1-4 Obesity Trials](https://cardiometabolicforum.com/storage/b2R66kMbWWtNzJ2xADlqxPzZTaChim0XZvI8LodL.jpg)
The Improved Health Utility of Once-Weekly Subcutaneous Semaglutide 2.4 mg Compared With Placebo in the STEP 1-4 Obesity Trials
![Publication thumbnail: Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk](https://cardiometabolicforum.com/storage/Dgvyq5Ia7lLbkIQvQfhYoJO1tnI3P5JUftBjNlIC.jpg)
Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk
![Publication thumbnail: Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials](https://cardiometabolicforum.com/storage/KePCUfN3k99CWw2PRvUVIVsub8d567aUIhQw8mK3.jpg)
Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials
![Publication thumbnail: Advances in the Management of Heart Failure with Reduced Ejection Fraction; The Role of SGLT2is, ARNI, Myotropes, Vericiguat, and Anti-inflammatory Agents: A Mini-review](https://cardiometabolicforum.com/storage/jRXRWoDSZzkkCTX463VFXmcvBtsxSZRD2ZCDVoxE.jpg)
Advances in the Management of Heart Failure with Reduced Ejection Fraction; The Role of SGLT2is, ARNI, Myotropes, Vericiguat, and Anti-inflammatory Agents: A Mini-review
![Publication thumbnail: Effects of Dapagliflozin on Hospitalisations in People with Type 2 Diabetes: Post-hoc Analyses of the DECLARE-TIMI 58 Trial](https://cardiometabolicforum.com/storage/g14uUhPEkJWqi8vs5D1nUPgaAGzg5JSuT3vACW0E.jpg)
Effects of Dapagliflozin on Hospitalisations in People with Type 2 Diabetes: Post-hoc Analyses of the DECLARE-TIMI 58 Trial
![Publication thumbnail: Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis](https://cardiometabolicforum.com/storage/Eg27v6DWHOYbsEkYQEgkmxwml09jYq5XtqFT6eTM.jpg)
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis
![Publication thumbnail: Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From the EMPEROR-Preserved Trial](https://cardiometabolicforum.com/storage/Gc3YDuouAFx1EF7acC07lMBKxZkSzmfVzSoXhvBT.jpg)
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From the EMPEROR-Preserved Trial
![Publication thumbnail: Benefits and Harms of Drug Treatment for Type 2 Diabetes: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials](https://cardiometabolicforum.com/storage/bnD88VNwmZbA9nHUUPZtn9gcGTnOEsuk77mhfPYH.jpg)
Benefits and Harms of Drug Treatment for Type 2 Diabetes: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials
![Publication thumbnail: Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials](https://cardiometabolicforum.com/storage/LovOOsGK12UIu8vunugbUE9AtDEtZjutNAk36I50.jpg)